RxDoctor Payments Data

Samuel Amponsah

Psychiatric/Mental Health · Aberdeen, NJNPI 1285394262

Payments from drug & device makers

$1,358in general payments, 2019–2025

Across 86 payments — averaging $15.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$274
  • Johnson & Johnson$225
  • Otsuka America Pharmaceutical, Inc.$143
  • Neurocrine Biosciences, Inc.$135
  • Teva Pharmaceuticals USA, Inc.$129
  • E.r. Squibb & Sons, L.L.C.$127
  • plus $324 from 6 others

What the payments were for

  • Food & beverage$1,358100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,358 in reported general payments places this provider in the 70th percentile of 1,212 psychiatric/mental health providers in New Jersey.

See all psychiatric/mental health providers in New Jersey

Medicare billing

Part B allowed, 2024
$41,523
Medicare patients
135
Services billed
383

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Abilify MaintenaAripiprazole34$91,100
Invega SustennaPaliperidone Palmitate44$90,189
AustedoDeutetrabenazine11$80,946
RexultiBrexpiprazole36$60,226
CaplytaLumateperone Tosylate12$22,303
VraylarCariprazine Hcl14$21,034
Paliperidone ErPaliperidone29$7,493
Aripiprazole105$3,941
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl14$3,623
Quetiapine Fumarate199$2,824
Divalproex Sodium ErDivalproex Sodium72$2,545
Divalproex Sodium55$1,658
Clozapine16$1,375
Thioridazine Hcl12$1,257
Haloperidol45$1,211

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$143$151,32670 claims
Johnson & JohnsonInvega Sustenna$225$90,18944 claims
Teva Pharmaceuticals USA, Inc.Austedo$129$80,94611 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$85$22,30312 claims
AbbVieVraylar$274$21,03414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,212 psychiatric/mental health providers in New Jersey.

Other psychiatric/mental health in Aberdeen

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →